PT-141
Bremelanotide
PT-141 (Bremelanotide) is an FDA-approved melanocortin receptor agonist specifically designed to treat hypoactive sexual desire disorder in premenopausal women. Unlike other sexual health treatments, PT-141 works through the central nervous system to enhance sexual desire and arousal rather than affecting blood flow or hormones.
Complete Dosing Guide
Quick Reference
1.75
Typical Dose
Variable
Frequency
2.7
Half-Life
SubQ
Route
Administration Method
Subcutaneous auto-injector (Vyleesi) in abdomen or thigh
Step-by-Step Dosing Protocol
As Needed
1.75 mg subcutaneous
Therapeutic dose
Administer ≥45 minutes before anticipated sexual activity
Frequency
Maximum 8 doses/month
Safety limitation
Do not exceed 1 dose per 24-hour period
Timing
45+ minutes before
Optimal efficacy
Allow adequate time for absorption and CNS effects
Maximum
8 injections monthly
FDA safety limit
Track usage to avoid exceeding monthly maximum
Dosage Calculator
Dose Calculator
Peptide amount must be greater than 0
Medical Disclaimer
Clinical data presented is from peer-reviewed studies. Individual results may vary. Consult healthcare professionals before starting treatment. This information is for educational purposes only.